**MKP: Annual General Mandate 2024**

On April 25, 2024, Mekophar Chemical Pharmaceutical Joint Stock Company announced General Mandate No. 32/NQ-DHDCD as follows:

Article 1. Approve the report on production and business results in 2023 and directions for 2024:

* Consolidated production and business results in 2023:

Revenue: VND 904,747 million

Profit before tax: VND 43,314 million

Dividends in 2023: 5%/share.

* Plan for consolidated production and business activities in 2024:

Revenue: VND 900,000 million

Profit before tax: VND 50,000 million

Dividends in 2024: 8%/share.

Article 2. Approve the report on Board of Directors activities in 2023 and directions for 2024:

Article 3. Approve the audited report on financial results 2023:

Article 4. Approve the Proposal on profit distribution and dividend distribution plan for 2023:

1. Total profit in 2023: 43,314,331,519
2. Total profit after tax: 25,114,127,514
3. Expenses for the executive Board of Directors and Supervisory Board in 2023: 408,000,000
4. The remaining profits distributed: 24,706,127,514
5. Expected appropriation for funds: 5,929,470,603

* Development and investment fund (8%): 1,976,490,201
* Bonus and welfare fund (16%): 3,952,980,402

1. Remaining profit for dividend payment in 2023: 18,776,656,911
2. Undistributed profits of previous years: 8,395,912,898
3. Total profit used for dividend payment: 27,172,569,809
4. Expected cash dividend rate in 2023 is 5%/share: 12,634,110,500
5. Remaining profit transferred to 2024: 14,538,459,309

Article 5. Approve the report of the Supervisory Board:

Article 6. Approve the Proposal:

Agree to authorize the Board of Directors to select 01 of 05 Audit companies for 2024 from the following Audit companies:

1. Auditing & Informatic Services Company Limited (AISC).
2. AASC Auditing Firm Company Limited.
3. AFC Vietnam Auditing Company Limited (AFC).
4. Ernst & Young Vietnam Limited.
5. A&C Auditing and Consulting Company Limited.

Article 7. Approve the Proposal to amend and supplement the Charter:

Article 8. Approve the Proposal to amend and supplement the operating regulations of the Board of Directors:

Article 9. Approve the Proposal to amend and supplement the Internal Regulations on corporate governance:

Article 10. Approve the Proposal:

* Operating expenses of the Board of Directors and Supervisory Board are 0.3% of net production revenue in 2024.
* Reward the Board of Directors, the Executive Board and the Supervisory Board with a bonus of 5% on profits exceeding the plan in 2024.

Article 11. Approve the Proposal on issuance of shares under the Company's ESOP.

1. Purpose of issuing shares:

* Aligning the interests of employees and the Company, serving as the foundation for the strong and sustainable development of the Company.
* Increase charter capital to supplement owners' equity to serve the Company's production and business needs.

1. Offering plan:
   1. Share name: shares of Mekophar Chemical Pharmaceutical Joint Stock Company
   2. Share code: MKP
   3. Share type: Common shares
   4. Number of issued shares: 25,545,867 shares
   5. Number of outstanding shares: 25,268,221 shares
   6. Number of treasury shares (as of December 31, 2023): 277,646 shares.
   7. Number of shares expected to be issued: 1,230,000 shares
   8. Total issue value at par value: VND 12,300,000,000
   9. Issuance rate (number of shares expected to be issued/number of outstanding shares): 4.87%
   10. Offering price: VND 15,000/share
   11. Expected proceeds: VND 18,450,000,000
   12. Time of issuance: Expected in Q3/2024
   13. Objects and methods of offering: Distribute according to the ESOP.

* Criteria: Competent, experienced employees with achievements and long-term dedication to the Company.
* The Board of Directors considers and decides based on the Company's Regulations on offering shares to Employees.
  1. Transfer restrictions: Shares can only be transferred after 5 years from the date of completion of the offering. The reselling or repurchase of shares by employees who have purchased ESOP shares in violation of regulations on transfer restrictions will be carried out in accordance with the Issuance Regulations issued by the Board of Directors.
  2. The number of shares that employees are approved to buy but refuse to buy will be considered by the Board of Directors for continued distribution to other employees.

Plan to use the proceeds from the offering: The capital obtained from the offering will be added by the Company to the Company's capital for production and business activities immediately after completing the reporting of the offering results to the State Securities Commission.

Article 12. Approve the Proposal on dismissal of members of the Board of Directors and additional election to replace members of the Board of Directors for the remaining period of term V (2020-2024).

Article 13. Approve the Proposal on the List and resume of candidates, nominating personnel to elect additional members of the Board of Directors for the remaining period of term V (2020-2024).

Article 14. Results of additional election to replace members of the Board of Directors term V (2020-2024) according to cumulative voting method:

|  |  |
| --- | --- |
| No. | Full name |
| 01 | Ms. Lu Thi Khanh Tran |

Article 15. This General Mandate was approved by the General Meeting of Shareholders and takes effect from April 25, 2024. The General Meeting of Shareholders authorizes the Board of Directors to concretize plans and tasks to direct the implementation of the General Mandate.